Introduction
Sarcoidosis is a multisystem granulomatous disease were performed on approximately 60% of all deaths, and histological evidence of sarcoidosis was found of unknown aetiology which has a propensity for the lungs, and relatively rarely, the nervous system. in 43 individuals, only three of whom were known to have sarcoidosis during life, yielding a prevalence Prevalence rates for intrathoracic sarcoidosis vary from greater than 50 per 100 000, for example in of 641 per 100 000 at post-mortem.2 Previous data from large series of patients with sarcoidosis have New York Blacks, to under 10 per 100 000.1 Intermediate estimates of 10-20 per 100 000 are estimated that approximately 5% of such patients will have clinical involvement of the nervous likely for Caucasians in London and New York, largely based on results from mass chest radiography.
system,3-6 although post-mortem studies suggest that ante-mortem diagnosis is only made in 50% with That the disease is frequently asymptomatic is suggested by a Scandinavian study when post-mortems nervous system involvement.7
The criteria upon which a clinical diagnosis of case notes by two investigators ( JZ and JS). The gold standard for establishing the diagnosis was taken as neurosarcoidosis is made have not been firmly established in the absence of positive nervous system the presence of positive nervous system histology in the absence of an alternative cause for the patient's histology; considerable variation has existed between series of patients with the disease, although the clinical condition, and these patients were labelled as having definite neurosarcoidosis. Positive nervous criteria commonly accepted are a clinical picture compatible with neurosarcoidosis, exclusion of other system histology is defined by the presence of sarcoid-type granulomas with epithelioid cells and neurological disease and histological confirmation of disease elsewhere. Newer diagnostic techniques, macrophages in the centre of non-caseating lesions surrounded by lymphocytes, plasma cells and mast including magnetic resonance imaging and investigations to exclude other causes of granulomatous cells. There may be a variable fibrotic response, and mycobacteria or other causes for the granulomatous diseases must be encompassed in any attempt to refine such criteria further. Not surprisingly, effective response should not be present.8,9 Based on our experience of investigating patients with suspected means of treating the condition, beyond the use of corticosteroids, have not been established. We report and proven neurosarcoidosis, and our scrutiny of the 68 patients presented in this paper, we propose a large number of patients with neurosarcoidosis who have been divided into diagnostic groups criteria for the diagnosis of 'definite' and 'probable' neurosarcoidosis, outlined in Table 1 . according to the certainty with which a diagnosis can be made. The major purpose of this retrospective Particular attention was paid to initial presentation, the presence or absence of systemic disease either review of clinical cases was to produce initial diagnostic criteria which could be modified in the prior or subsequent to neurological presentation, investigation findings, length of follow-up and therafuture and act as the foundation for a more detailed prospective analysis. This review therefore covers peutic measures used to control the disease. An estimate of the overall clinical progression during the clinical features, investigations including MRI findings and treatment schedules of what we have the follow-up period was made retrospectively by deciding whether the treatment had improved, stabildefined as 'definite' and 'probable' neurosarcoidosis. Regimens which could form the basis for therapeutic ized, or had little impact on the disease between presentation and most recent clinical review. Only options in the event of troublesome disease are also considered, based on current knowledge, although patients followed for a minimum of 18 months were assessed in this fashion. data for rational, informed decisions are lacking.
Data from those patients with biopsy-proven disease in the CNS were also analysed separately to assess whether this group of patients with definite
Methods
Case notes were examined from patients at the Department of Neurology, Addenbrooke's Hospital, 
Patient details
(Appendix I). Further detailed information concerning visual acuities was available in 16 patients who were Sixty-eight patients were identified as having definite followed-up for at least 18 months. Thirteen of these or probable neurosarcoidosis, 49 from the National patients had visual acuities of 6/18 or worse in at Hospital and 19 from Addenbrooke's Hospital.
least one eye at presentation. Over the follow-up Thirty-six (53%) patients were male and 32 (47%) period, five patients showed a deterioration to at female. Mean age at presentation was 38.9 years least 6/60, five patients improved to at least 6/9 and (range 21-64 years). Twelve of the 68 (17.7%) had three patients showed no significant change from histological confirmation from CNS tissue in the their presentation acuity. As all these patients absence of any other identifiable cause, and thus received corticosteroid treatment, these data would fulfilled the criteria for definite neurosarcoidosis. The suggest an approximate 40% chance of appreciable average length of follow-up was 4.6 years (range 2 recovery over long-term follow-up with this therapy. months-18 years). Forty-seven of 68 (69%) patients
The large number of ophthalmological presentations were followed-up for a period of >18 months.
in this series may reflect the links between the National Hospital and a nearby specialist Eye
Clinical presentation
Hospital.
The second most common presenting feature in Twenty-six patients (38%) had sarcoidosis previously the series was other cranial nerve palsies in one diagnosed in another organ. Most commonly this third of patients. If optic nerve disease is also taken was confined to the chest or anterior uvea, but 62% into account, then 72% of patients presented with of patients in this series had central nervous system cranial nerve palsies. The nerves involved are shown involvement at the time of their initial referral. Details in Figure 2 . Thirteen patients (19%) had facial nerve of clinical features when first seen with CNS disease paralysis; eight of these were unilateral palsies, two are summarized in Figure 1 .
were bilateral and simultaneous, two were recurrent Twenty-six patients (38%) had evidence of optic on the same side and there was one case of nerve disease at presentation with CNS disease; sequential palsy initially on the left and then invol-18/26 (69%) had clinical evidence of unilateral and ving the right within weeks. Only seven patients 8/26 (31%) bilateral disease. The characteristic picture was one of an atypical optic neuritis, often who presented with facial nerve palsies were fol- Details of spinal fluid analysis were available in 62 patients. Forty-five (73%) showed elevated protein levels Á0.5 g/l, which did not appear to correlate with clinical phenotype. In 34 samples (55%) there was a raised leucocyte count (Á5 cells/mm3, range 5-220), which was usually a lymphocytosis. Thus 50 (81%) patients had either an elevation of their age-adjusted CSF protein levels and/or a pleocytosis. CSF glucose analysis was available in 46 patients, 44 of whom had normal levels (>40% serum level). Two had low glucose: 2.4 mmol/l in CSF against 7.6 mmol/l in serum, and 0.29 mmol/l in CSF against serum concentration of 5 mmol/l. CSF ACE was assessed in 18, and was outside the normal laboratory range for CSF ACE in six. Isoelectric focusing of CSF had evidence for local synthesis (37%), while 10 patients (18.5%) showed serum and CSF oligoclonal lowed up for more than 18 months; five deteriorated bands, indicative of systemic synthesis. or died over this period and two stabilized.
Serum ACE was elevated in 12/51 cases (23.5%). Nineteen patients (28%) exhibited clinical signs
Other biochemical indices were unhelpful in estabof spinal cord disease. In 10 patients this was lishing a diagnosis. Serum calcium was normal in clinically confined to the cord, while nine patients all and erythrocyte sedimentation rate was elevated also had clinical disease elsewhere in the neuraxis in four patients. (Appendix I, patients 3 and 4). Fifteen cases with Gallium 67 scanning to look for tracer uptake in spinal cord disease were followed-up for more than salivary and lacrymal glands, chest and spleen was 18 months, and 11 of these deteriorated (73%).
performed in 31 patients, and proved informative in Brainstem and/or cerebellar presentations occurred 14 patients (45%). in 14 patients (21%) who principally exhibited limb or gait ataxia and eye movement abnormalities such as failure of vertical gaze. One such presentation is detailed as patient 5. (Appendix I). There was one
CT and MRI
instance of central vomiting. There were seven MRI or CT scans were available for review in 44 examples (10%) of cognitive decline and eight of a patients, eight of whom fulfilled the proposed criteria meningitic-type illness in the series at CNS prefor definite neurosarcoidosis. The T2 weighted cranial sentation.
MRIs of 37 patients (seven definite), were reviewed along with gadolinium-enhanced T1-weighted scans Investigations in 29 patients; 11 patients had spinal MRI. Cranial CT was carried out in 20 patients, with contrast All patients had a chest radiograph at presentation, and 21/68 (31%) were abnormal. The most common enhancement in 15. Seven patients had brain CT without MRI. The results of the MRI review are abnormality was bilateral hilar lymphadenopathy, seen in 19 patients (28%), four of whom had some shown in Figure 3 . The most common abnormality on MRI was mulpulmonary abnormality in addition. There were two cases of pulmonary shadowing in the absence of tiple white-matter lesions, which were present in 16, 43% of the patients whose scans were reviewed. An obvious lymphadenopathy.
Kveim tests were performed in 48/68 patients example of this is shown in Figure 4 (patient 3, Appendix I). Meningeal enhancement occurred in (71%), 41 (85%) of which were histologically positive and seven (15%) negative. A single antigen source 11/29 (38%) of those studied and 4/7 (57%) of the 'definite' patients. Figures 5 and 6 (patient 2) illustrate was used in all the Kveim tests, produced from a spleen removed in 1981. All seven of the Kveimmeningeal enhancement. Figure 6 also shows optic nerve enhancement, which was seen in eight patients negative patients were being treated with systemic corticosteroids. One patient had definite disease with (28%). Examples of spinal cord involvement are shown in Figures 7 (patient 4) and 8. CT generally a negative Kveim test. This man presented with a convulsion, and was found to have a large contrast produced less information than MRI, particularly in the posterior fossa. Pathological meningeal contrast enhancing mass in the left temporal region which showed typical non-caseating granulomata on enhancement occurred on CT in four patients (20%), white-matter lesions were detected in six (30%) and biopsy. lesions of the optic nerve or chiasm were seen in in neurosarcoidosis is corticosteroids, and 34 patients received this therapy alone, usually as a combination two (10%).
There were 13 patients who had both CT and long-term oral prednisolone with or without intravenous methylprednisolone boluses. Ten (29%) MRI and in 11 both investigations were abnormal. In two, cranial CT was normal while MRI was improved or stabilized, whereas 24 (71%) deteriorated. Other therapies were tried only when steroid abnormal, implying a greater sensitivity of MRI for detecting lesions consistent with neurosarcoidosis. treatment was becoming ineffective or side-effects were too severe; such treatments included methotrexate, azathioprine and hydroxychloroquine (the latter 'Definite' neurosarcoidosis was taken by two patients in association with methoTwelve patients fulfilled the criteria for definite trexate and corticosteroids). The number of patients neurosarcoidosis. The clinical presentation and treated with any other single regimen was too small investigation results on this group of patients are to draw firm conclusions. Cyclosporin was used in shown in Table 2 . Particular attention was paid to three instances and was associated with improvement this group of patients in an effort to validate the in one case. Cranial irradiation was used in two usefulness of specific investigations. Histological diainstances, in one patient after cyclosporin had failed gnosis was obtained from meningeal biopsy in 6/12 and in another after corticosteroids proved ineffectcases, from brain parenchymal biopsy in 3/12, spinal ive. Intravenous cyclophosphamide was used at high cord biopsy in 2/12 and optic nerve biopsy in one dosage (400 mg/day until the peripheral white-cell case. The Kveim test was positive in 6/7 patients count fell to below 4×106/ml) in three patients, (compared to 35/41 in the probable cases), an who all improved. abnormal CSF protein was found in 6/8 (compared to 39/54 in the probable cases) and the cell count was raised in 4/8 (compared to 30/54 in the probable Discussion cases). Chest radiography was abnormal in 4/12 patients; gallium 67 scanning was abnormal in 2/3 Diagnosis of neurosarcoidosis patients studied. MRI was done in seven definite A confident diagnosis of neurosarcoidosis is often cases: three of these showed parenchymal involvedifficult, particularly when the clinician is presented ment, four had meningeal enhancement, three diswith an isolated central nervous system disorder played hydrocephalus, two displayed white-matter which is likely to have an inflammatory basis. The lesions, and there was one example each of optic nervous system is a relatively uncommon site for the nerve and spinal cord involvement.
disease to manifest and as a consequence, investigation to establish a diagnosis has centred on search-
Treatment and clinical course
ing for histological confirmation in other organs. In the present paper we have adopted criteria for We felt that no valid observations could be made concerning the effectiveness of treatment unless making the diagnosis of neurosarcoidosis based upon clinical certainty; thus in order to fulfill conditions patients had been followed-up for at least 18 months. Forty-seven patients meeting this criterion were anafor definite disease the patient must have an appropriate clinical syndrome with positive nervous system lysed according to treatment received and overall clinical course. The mainstay of medical treatment histology in the absence of any other cause. Probable disease has then been defined according to various sclerosis with optic nerve, spinal cord or brainstem disease; other diseases may exhibit clinical features indirect indicators of disease as outlined in Table 1 . These criteria are considerably stricter than in previous similar to those of neurosarcoidosis and these include Lyme disease (with facial nerve palsies and root series, but we feel a more rigorous definition is necessary for a number of reasons. Most important irritation syndromes), Wegener's granulomatosis (with meningeal involvement), Behcet's disease, meningeal among these is the possibility of alternative explanations for neurological syndromes in patients with carcinomatosis, tuberculosis and lymphomatosis. prognostic indicators, and better assessment and It was hoped that a large number of cases would be obtained which fulfilled the criteria for definite validation of indirect indicators of disease, but also enables therapeutic trials to be conducted in a disease, which could then be used as the 'gold standard' to assess the usefulness of any single meaningful fashion. However, biopsy of CNS tissue is required to make a definite diagnosis of neurosarinvestigation. However, when assessing such a group, bias is inevitably introduced, as biopsy is undertaken coidosis. When the patient is seriously ill with rapidly progressive disease in several parts of the neuraxis, selectively, e.g. on mass lesions, where the possibility of neoplasia has been raised, in patients with severe it is important to achieve a diagnosis as quickly as possible in order that appropriate therapy can be and rapidly progressive disease or in cases where histology is relatively easy to obtain. The site of commenced, and under these circumstances guided stereotactic or open biopsy is often performed, either lesions (which influences the decision to biopsy) will also influence the clinical presentation-for example, of meninges and/or of parenchymal lesions. With less severe disease and/or a more gradual course, it cortical lesions may be more likely to present with epilepsy and be biopsied, thus interpretation of the is often more appropriate to perform indirect investigations to look for systemic disease and treat accordclinical presentation of this group of patients must be cautious. Another major difficulty with interpreting ingly (see below). data from these patients is the incomplete data Clinical presentations available, as investigations are often halted once tissue diagnosis is achieved. Notwithstanding these
In the present series, there was a high prevalence of limitations, they do confirm the usefulness of the optic nerve disease at presentation with CNS disease. Kveim test and CSF analysis in the investigation of Although this partly reflects the referral bias of one of the physicians (who jointly attends the Moorfields neurosarcoidosis.
by guest on October 5, 2016 Downloaded from be severe, with profound impairment of visual acuity being all too common. Of the patients who presented with impaired visual acuity and were followed-up for at least 18 months, appreciable recovery occurred in fewer than half.
Facial nerve palsies are a classical manifestation of neurosarcoidosis and have been reported as carrying a good prognosis in previous publications.5 Although sarcoidosis does not appear to feature prominently among the causes of facial nerve palsies in large series,10,11 there has not been a large prospective analysis of such patients looking specifically for sarcoidosis. Relatively little comment can be made on the prognosis of neurosarcoidosis presenting with facial palsy based on the current series, in view of the relatively small number of patients in whom long-term follow-up data were available. It was certainly our impression that isolated facial nerve palsies carried a more favourable prognosis than other manifestations of the disease. There may well be a difference in prognosis depending on where the facial nerve is affected along its course. Certainly examples of CSF abnormalities in cases of apparently pure facial palsy in the present series suggest that the lesion may result from a meningitic reaction, but the classical explanation for facial palsy in neurosarcoidosis is that it is secondary to inflammation in the parotid gland, although many early authors also noted the lack of temporal correlation between parotitis and facial palsy.12 More detailed prospective studies are clearly needed to assess the site and significance of such palsies.
Spinal cord disease was found in 28% of patients at initial neurological presentation. Previous large series have reported prevalence levels of up to 10%.6,13,14 Syndromes ranged from intramedullary tumour-like presentations to meningitic-radicular syndromes.15 Fifteen cases of spinal cord disease were followed-up for more than 18 months in the present series and results suggest that such a presentation carries a poorer prognosis than certain other 
Investigation of possible neurosarcoidosis
Eye Hospital and the National Hospital), previous series have confirmed the anterior visual pathways
Establishing the diagnosis of neurosarcoidosis may be difficult, and the only way to acquire firm as a site of predilection for neurosarcoid, often second only to the facial nerve. When investigating evidence for the value of any single investigation is to perform a prospective study using appropriate patients for neurosarcoidosis, a full neuro-ophthalmological workup is indicated, including a search investigations in all patients, especially those in whom a definite histological diagnosis has been for both anterior and posterior segment disease, with slit-lamp examination and fluorescein angiography, obtained. The understandable tendency not to perform further investigations once the diagnosis has as well as seeking clinical and/or visual evoked potential evidence for optic nerve disease.
been obtained has limited our knowledge on the usefulness of non-invasive methods for investigating Unfortunately, optic nerve disease has a tendency to neurosarcoidosis. In the present retrospective series, Kveim test can be regarded as comparable to that of finding granulomas in a biopsy of a site remote from the most useful investigation continues to be the Kveim antigen skin test, which was positive in 85% that principally affected, and compared with other positive tissue biopsies, it has the advantage of an of patients who were tested. This compares favourably with rates of positivity in other patients with added degree of selectivity for sarcoidosis appropriate to a carefully validated Kveim test suspension. The usefulness of performing 'blind' biopsies from who concluded that local synthesis was an uncommon event. However, neither of these studies had other organs, including liver and lung, in patients with suspected neurosarcoidosis, is uncertain. Three such a large number of patients. The significance of raised CSF ACE levels in the patients in the present series had a liver biopsy although only one patient of the three had abnormal context of elevated protein concentrations or CSF cell counts remains uncertain. In the present series, liver enzymes. All biopsies showed sarcoid granulomas in these three patients. While tissue diagnosis these results were abnormal in 33% of cases, a lower level than in previous studies,20 and perhaps disfrom sites outside the nervous system has previously been considered sufficient to establish the diagnosis appointing given the sensitivity of serum ACE for pulmonary sarcoidosis. We believe their usefulness of neurosarcoidosis in the context of an appropriate clinical syndrome, we would still only consider this may be principally confined to that small number of patients where levels are raised out of proportion to as evidence of systemic disease, which by itself is insufficient to be certain of neurological involvement the protein concentration, when the CSF does not contain large numbers of inflammatory cells and the by granulomatous tissue.
CSF abnormalities are common in neurosarcoserum ACE is not elevated. The best estimate would be an ACE index analagous to the IgG index idosis, and were present in over 80% of cases at presentation. The most common abnormality was an (CSF/serum ACE divided by CSF/serum albumin). Whole-body gallium scanning remains a useful elevation in protein (when 0.5 g/l was taken as the upper limit of normality), sometimes to very high indicator of systemic disease, which although again is a relatively non-specific measure, adds diagnostic levels, indicative of blood brain barrier dysfunction. Fifty-five percent of patients demonstrated a CSF probability to a case. Ga-67 citrate is taken up at sites of active sarcoidosis and also by other inflamlymphocytosis, with occasional rare neutrophils and monocytes. Taken together, 50/62 (81%) demonmatory and malignant diseases, including tuberculosis and lymphomas, but the pattern of uptake strated either an elevation of CSF protein levels and/or pleocytosis. Fifty-five percent of patients had among patients with active sarcoidosis is well recognized. Accordingly, as a component of the investi-CSF oligoclonal bands: one-third of these cases provided evidence for systemic synthesis, and twogations relevant to the diagnosis of extrathoracic sarcoidosis, it can be very helpful, although conthirds fulfilled the criteria for local synthesis. Only strained by the limitations imposed by subjective systemic corticosteroids, which often carry significant side-effects, as dosages tend to be high and prointerpretation. In a consecutive unpublished series of 42 (independent of the present study) such longed. Although some patients improve on this treatment, many continue to have troublesome dispatients, a definite pattern of uptake was obtained in 18 (42%), whilst the pattern of uptake was ease, in the present series over 70%. It was particularly noticeable in the present series that symptoms considered equivocal in eight and negative in 16. In the current series, 45% of patients in whom this tended to recur at doses of prednisolone less than 20-25 mg/day or the equivalent in other corticoinvestigation was performed proved to have increased uptake, which was usually in the salivary steroid types, making cessation of corticosteroids difficult. The incidence of steroid-related side-effects glands or chest. Only three patients had increased uptake in the cranium. Chest radiographs were is extremely high with such prolonged treatment. Concomitant anticonvulsant therapy which induces positive in 30% and were helpful in diagnosis, although not especially sensitive. Chest CT was hepatic microsomal enzymes may reduce prednisolone concentration and efficacy, necessitating even performed too infrequently in our series to pass comment on, although previous studies suggest it higher oral doses. Bolus pulsed intravenous methylprednisolone gives a high initial loading dose of may assist in targeting transbronchial biopsy.
MRI has greatly aided the investigation of patients corticosteroid, and may help to avoid the side-effects associated with long-term oral treatment. We also with inflammatory brain disease and has again proved to be more sensitive than CT in the present have the impression that it sometimes modifies the disease, allowing lower doses of oral therapy to be series. The range of abnormalities included whitematter lesions, hydrocephalus, mass lesions in used thereafter. Even fewer data exist concerning the efficacy of the brain parenchyma, meningeal enhancement, enhancement of parenchymal lesions and lesions of other forms of immunomodulatory therapy. The use of chlorambucil,24 methotrexate,25,26 chloroquine,27 the optic nerves and spinal cord, with or without enlargement of these structures. All these abnormalitcyclosporin,28-30 radiotherapy,31-33 and in this series cyclophosphamide, have all been reported. Our ies have been described in previous smaller series. [21] [22] [23] The distinction of neurosarcoidosis from MS can recent experience suggests that methotrexate, usually used weekly at an oral dose of 10 mg, may be of sometimes be very difficult. Although none of the appearances are specific for neurosarcoidosis, meninvalue in maintaining optimal suppression together with i.v./oral prednisolone, and we often use this as geal enhancement or persistent enhancement (more than a few weeks) of parenchymal lesions are much a first-line steroid-sparing agent. Hydroxychloroquine has also proved to be a very useful adjunct more suggestive of a granulomatous process, and are not expected in MS. Occasionally, white-matter to steroids, and at a dose of 200 mg/day the Ophthalmological Society has approved its use withlesions are seen in sarcoidosis which are indistinguishable from MS.
out recourse to examination with red light. This can be used daily for up to about a year and is worth It is recognized that the diagnostic criteria suggested here will inevitably exclude a number of considering as a first-line agent together with methotrexate. We would consider cyclosporin, cyclophospatients with neurosarcoidosis. However, the further detailed prospective study of patients, so defined, phamide and fractionated radiotherapy, which all need further assessment. Our current management may permit identification of diagnostic factors and patterns which will assist in the diagnosis of milder of neurosarcoidosis usually consists of initiating treatment with 1 g i.v. methylprednisolone for three days or atypical forms of the disease.
together with at least 25 mg oral prednisolone or equivalent per day. Intravenous methylprednisolone Treatment and prognosis in (1 g ) is then continued on a weekly basis for a neurosarcoidosis number of weeks, allowing a reduction of oral prednisolone to 15-20 mg/day. During this period, Although this is the largest single series of patients with neurosarcoidosis yet reported, with the most oral methotrexate and hydroxychloroquine may be added, especially with severe disease or a poor extensive follow-up details, it remains impossible to identify those patients in whom early aggressive initial response to steroids. In severe cases, the i.v. methylprednisolone may be continued for some immunotherapy would be beneficial. As no prospective data are available in this condition, analysis of months, with a gradually increasing inter-dose interval. However, it must be emphasized that clear the current series and previous publications would suggest that disease presenting in the spinal cord or guidelines and indications for treatment together with the drugs which should be used in different clinical optic nerve, together with epilepsy, carry a poorer prognosis than facial nerve palsies. Most patients in circumstances remain matters for further scientific enquiry. this and previous series have been treated with by guest on October 5, 2016 Downloaded from eye. At that stage there was no perception of light Appendix I: Case histories in the left eye and the fundus showed a swollen disc with peri-papillary haemorrhage. Routine blood and
Patient 1
CSF investigations were normal, with no oligoclonal A 30-year-old office worker born in England of Afrobands detectable. MRI showed thickening of the left Caribbean descent noticed that his right pupil was optic nerve extending from behind the globe to larger than the left in April 1993. He had become the chiasm with abnormal contrast enhancement. aware of light-associated discomfort and redness of Transection and biopsy of the optic nerve demonthe right eye which was subsequently diagnosed as strated non-caseating granulomas with multinucleate anterior uveitis and treated with steroid eye drops. giant cells, confirming the diagnosis of optic nerve His symptoms improved within 6 weeks and his eye sarcoidosis. The patient was initially treated with drops were stopped. Four months later he developed intravenous methyl prednisolone followed by oral a further subacute deterioration in the vision of his prednisolone. Within a year after her operation she right eye, associated with pain and alteration of was taking 40 mg of prednisolone on alternate days colour vision. Examination revealed an acuity of but a slight reduction in the visual acuity combined 6/60 on the right and 6/9 on the left, with an inability with a field defect in the right eye necessitated the to identify any Isihara test plates on the affected side.
introduction of azathiaprine 150 mg/day. This was There was a right afferent pupillary defect with well tolerated, and allowed further reductions in bilateral central scotomas and no other neurologsteroid dosage, as spontaneous bone fractures had ical signs. become a problem. Two and a half years after the Investigations revealed bilateral hilar lymphadenointroduction of Azathioprine her visual acuity was pathy with reticular-nodular shadowing in both lung 6/12 and there was no clinical indication of active fields on conventional radiography and chest CT.
disease. Blood investigations revealed normal liver function tests, negative autoantibodies, including antineutrophil cytoplasmic antibody (ANCA), but mildly
Patient 3
elevated serum ACE at 89 IU/l (52-82 IU/l). Visual A 27-year-old man of Middle-Eastern extraction evoked responses were unobtainable but pattern developed bilateral anterior uveitis which responded reversal electroretinogram was within normal limits to treatment with steroid eye drops. A year later he bilaterally, suggesting optic nerve disease. CSF developed gradually increasing weakness of his legs showed an elevated protein and pleoocytosis (14 with urinary symptoms, impotence and an abdominal lymphocytes, two neutrophils). MRI showed sensory level. CSF at the time showed 19 lymphothickened gadolinium-enhancing meninges over both cytes and a protein of 0.7 g/l. Kveim test was positive cerebral hemispheres and marked thickening of the and myelogram demonstrated an expansion of the right optic nerve, also with gadolinium enhancement. thoracic cord. Cranial T2-weighted MRI revealed Transbronchial biopsy at bronchoscopy showed charmultiple areas of high signal intensity, predominantly acteristic granulomas, and the patient was comin the white matter, although some also involved the menced on oral prenisolone, 60 mg/day. Over the cortex. There was also abnormal high signal on following year, the visual acuity in the right eye T2-weighted images within the cord at the midimproved back to 6/5 but attempts to reduce the thoracic level. He was commenced on oral prednisooral prednisolone below 20 mg/day resulted in a lone after a course of intravenous therapy which recurrence of symptoms. A central scotoma persisted improved his leg spasticity somewhat, but attempts throughout this period, and the patient experienced to reduce the dose to less than 30 mg/day led to a steroid-related side-effects.
worsening of his symptoms. His disease slowly progressed over the course of the next 9 years, but clinically appeared to be confined to the spinal cord.
Patient 2
MRI 7 years after the onset of his neurological disease again demonstrated numerous areas of high A 54-year-old Caucasian housewife experienced gradual painful visual loss in her left eye over the signal within the white matter, many of which were periventricular, and a high proportion of which course of 9 months, associated with a rippling effect in her visual field. At the time there were no enhanced with gadolinium. There was also abnormal enhancement of the meninges covering the temporal associated neurological abnormalities on examination outside the visual system. Temporal artery biopsy lobes, but no basal enhancement. On sagittal T2-weighted fast spin echo images, there was an was normal, and a course of intravenous methyl prednisolone made no difference to her blindness.
area of high signal of the cord opposite T5 and T6, which had changed little since the original examThe pain became much worse 7 months after the onset, and was exacerbated by adducting the left ination.
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Patient 4 Patient 5
A 27-year-old Caucasian man developed diplopia, A previously well 49-year-old Caucasian company director started to experience band-like sensory phenan unsteady gait, left-sided facial weakness and a clumsy right arm over the course of 6 days. omena around his waist which progressed over the course of 4 months to produce difficulty in walking Examination revealed upbeat nystagmus in the primary position, a gaze palsy to the left and a right with sphincter dysfunction. Examination revealed a spastic paraparesis with a sensory level at T8. MRI internuclear ophthalmoplegia. Vertical gaze was also reduced. There was sensory loss over the second of the spinal column revealed an expanded spinal cord with pathological contrast enhancement at this and third divisions of the trigeminal nerve and a lower motorneurone facial nerve weakness on the site, which was felt to be an intramedullary tumour. A laminectomy was performed and biopsy showed left with gait ataxia. CSF analysis showed 7 lymphocytes, a protein of 1.56 g/l and positive Kveim test. the typical appearances of sarcoidosis. The patient was treated with oral prednisolone and intravenous MRI revealed a large lesion of high-signal intensity on T2-weighted images in the brainstem which cyclophosphamide at 400 mg/day until his peripheral leucocyte count fell to below 4×106/ml. When last showed pathological contrast enhancement within it. He derived some benefit from intravenous and reviewed, over 2 years after the presentation of his illness, he was virtually asymptomatic and able to oral prednisolone so that 2 years later his MRI was normal, but he was left with facial weakness and walk long distances unaided. He was maintained on 25 mg of prednisolone on alternate days together internuclear ophthalmoplegia. with amytriptyline for residual paraesthesiae.
